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Abstract 
In this report, two cases of uterine smooth muscle cell tumors, one of uncertain malignant potential and one clearly malignant, 
are described in women treated for prolonged periods with luteinizing hormone-releasing hormone (LH-RH) analogues. Due to 
lengthy monitoring of LH-RH therapy, surgical intervention and histologic lassification of these tumors was late in the course 
of disease, resulting in a delay in definite treatment. The risk to these women is discussed. The effects of LH-RH analogue therapy 
on fibroids is reviewed. Suggestions are put forward for monitoring LH-RH analogue therapy. 
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I. Introduction 
As tumor volume in both benign and malignant 
smooth muscle cell tumors of the uterine corpus has 
been shown to be oestrogen dependent, much research 
has been directed toward growth modification of these 
tumors with hormones. In recent years there has been 
increased interest in the application of luteinizing hor- 
mone-releasing hormone (LH-RH) agonists. These in- 
duce suppression of ovarian hormonal function and a 
hypoestrogenic state, inducing a reduction in fibroid 
volume which may exceed 50% [6]. The exact mecha- 
nism by which volume reduction is attained is at 
present unknown. However, this therapeutic approach 
is widely used. A drawback in treating fibroids with 
LH-RH analogues for long periods is that, in women 
who do not respond to therapy, there will considerable 
delay before surgical intervention and subsequent histo- 
logic evaluation of the uterine neoplasms. In the case of 
a leiomyofibroma, the delay will have no adverse ffect 
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for the patient. However, if the smooth muscle cell 
tumor is of uncertain malignant potential or malignant, 
the delay may have severe consequences. 
Two cases are illustrated in which treatment of uter- 
ine fibroids with LH-RH analogues led to a consider- 
able delay in histologic classification and possibly 
exposed patients to risk of which the severity is difficult 
to estimate. 
2. Case reports 
2.1. Case 1 
A 33-year-old primigravida with an uneventful past 
medical history presented with excessive menstrual 
bleeding while on sequential hormonal contraceptives. 
On physical examination, her uterus was the size of a 
14-week pregnancy. Ultrasonographic examination re- 
vealed a solid subserosal mass in the posterior wall of 
the uterus, the diameter was 9.8 cm. An endometrial 
curetting was normal. 
As the patient wished to preserve her fertility, she 
was treated for 6 months with an LH-RH analogue 
(Decapeptyl® Ferring, Haarlem, The Netherlands). The 
diameter of the uterine mass decreased to 4.9 cm. She 
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was seen at regular intervals for 1 year after comple- 
tion of the treatment. During this period she did not 
become pregnant. Ultrasonography performed at the 
end of this period revealed that the solid mass had 
increased in diameter and was 8.9 cm. Surgical re- 
moval was decided on. 
Three masses were enucleated; one was 0.9 cm, one 
was 2.5 cm and the third was 9 cm in diameter and 
weighed 330 g. All tumors had the same macroscopic 
features and firm rubbery consistency. From each tu- 
mor, excisions were taken at intervals of approxi- 
mately 1 cm and routine H&E stained sections were 
prepared. Microscopic examination revealed three tu- 
mors composed of whirling bundles of spindle-shaped 
smooth muscle cells. Sections from the largest myoma 
(Fig. 1), however, were different when compared 
with the smaller tumors in that there was mod- 
erate nuclear atypia and an average of 8 mitotic 
figures were counted in 10 consecutive fields (magnifi- 
cation, 400 x ). The diagnosis of a smooth 
muscle tumor of uncertain malignant potential was 
rendered. 
Further treatment consisted of a hysterectomy. No 
residual tumor was found in the uterine specimen. The 
patient is alive and well, 26 months after hysterec- 
tomy, with no evidence of disease. 
2.2. Case 2 
A 47-year-old woman, gravida 2, para 2, presented 
with severe blood loss leading to anaemia, requiring 
blood transfusions. On physical examination, the 
uterus was the size of a 10-week pregnancy. No addi- 
tional tests were performed. For the following 4 
months the patient was treated with Decapetyl® (Fer- 
ring Haarlem, The Netherlands). During therapy, uter- 
ine size decreased but the hypermenorrhoe r curred on 
cessation of hormonal treatment. Surgical intervention 
was decided on. 
The resected uterus was deformed and weighed 
800 g. Dissection revealed several well-delineated firm 
white-grey tumors between 1 and 7 cm in diameter 
and one less well delineated grey mass with a diameter 
of 4.5 cm and a soft putty-like consistency. Histologic 
examination of the former nodules showed features 
consistent with leiomyomas. The latter tumor was hy- 
percellular and composed of highly pleomorphic ells 
with a variable amount of eosinophilic ytoplasma nd 
large polymorphic nuclei. Dispersed bizarre giant cells 
were also seen. A maximum of 14 mitotic figures in 10 
consecutive fields (magnification, 400 x ) were counted 
(Fig. 2). There was no evidence of vascular invasion. 
A pleomorphic leiomyosarcoma was diagnosed. 
Further treatment consisted of abdominal radiother- 
apy. The patient is alive and well, 23 months after 
hysterectomy, with no evidence of disease. 
Fig. 1. Case 1 : smooth muscle cell tumor composed of elongated cells 
with uniform nuclei and eosinophilic cytoplasm. Several mitotic 
figures (arrows) are visible. 400 x ,  H&E. 
Discussion 
During the past 10 years, treatment of uterine 
leiomyomas with LH-RH analogues has become exten- 
sive [1 5]. These analogues are derivatives of the hypo- 
thalamic hormone LH-RH in which substitutions in the 
amino acid structure have made the analogue 40-200 
times more potent than naturally occuring LH-RH. 
The mechanism of their action is complex; however, 
they are thought o bind pituitary receptors, resulting in 
suppression of the pituitary-ovarian axis and inducing a 
state of pseudo-menopause. The resultant hypoestro- 
genemic state induces myoma regression. Furthermore, 
it is thought that LH-RH analogues have a direct 
inhibitory effect on smooth muscle cell growth [2]. 
During therapy, significant shrinkage is seen in most 
fibroids; smaller fibroids have even been shown to 
regress completely. On cessation of therapy, regrowth 
of fibroids occurs in premenopausal women. For this 
reason, LH-RH analogue therapy is given prior to 
operative therapy. The most important advantage of 
Fig. 2. Case 2: leiomyosarcoma, This neoplasm composed of highly 
atypical smooth muscle cells with many bizarre giant cells and 
scattered mitotic figures (arrow). 400 × , H&E. 
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this approach is that there is considerably less blood 
loss during surgery. Studies demonstrate that postope- 
rative fertility is improved after myomectomy in pa- 
tients previously treated with LH-RH analogues [3]. In 
perimenopausal women, surgery may be avoided due to 
the fact that the volume reduction of  the myoma will 
sufficiently alleviate symptoms from premenopause up 
to menopause, after which myomas usually regress 
spontaneously. 
In the two cases described, we demonstrate that this 
therapeutic approach may also have a number of  disad- 
vantages. Malignant and borderline malignant smooth 
muscle cell tumors causing symptoms may also be 
treated with LH-RH analogues prior to myomectomy 
or hysterectomy. This will cause considerable delay 
between diagnosis and histologic examination of  these 
myomas. The question is whether this approach entails 
any danger for the patient. In general, only very small 
numbers of  myomas are potentially malignant or 
clearly malignant. Diagnosing these tumors at a later 
date should not offset the net beneficial effect of  this 
valuable therapeutic approach. In the case of  a leiomy- 
oma of  borderline malignancy, it is not clear what effect 
delay in surgical intervention will have. In these tumors 
metastasis have not been described and their biological 
behaviour is not known [3]. 
In leiomyosarcoma, delay in diagnosis could be ex- 
pected to have a significant effect on patient outcome as 
disease may spread in the period during which the 
LH-RH analogue is given. However, very little is 
known regarding the metastatic potential of  a 
leimyosarcoma nd if LH-RH analogue treatment has 
any effect on metastatic potential [7]. 
It has been reported that gonadotropin-releasing hor- 
mones induce significant volume reductions in both 
benign and malignant smooth muscle cell tumors of  the 
uterine corpus. Quantitative morphologic evaluation of  
these tumors reveals a significant reduction in cellular- 
ity; however, fibrosis, edema or mitotic activity are not 
influenced. This implies that the same histological crite- 
ria may be applied to uterine smooth muscle tumors in 
women treated with LH-RH analogues as are applied 
to tumors in untreated patients [6,8]. 
There is no clinical parameter capable of  indicating 
the possible malignant potential of  a smooth muscle 
tumor at the beginning of  the hormonal  treatment [9]. 
Taking a thick needle biopsy prior to treatment is not 
recommended ue to sampling error associated with 
this approach. 
In summary, we feel that a careful clinical evaluation 
of  the patient is necessary during hormonal  therapy; 
this involves following both subjective and objective 
symptoms as well as tumor size. In case of  severe 
abdominal pain, persistent vaginal bleeding, increase in 
tumor size or no objective therapy response, short term 
surgical intervention should be seriously considered. 
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